AMCase has attracted immense attention for a novel biomarker due to increasing findings demonstrating its expression under specific pathological conditions and chronic severe inflammations, including gastric cancer, Crohn’s disease, and a chronic obstructive pulmonary disease [18,20,21]. This evidence concerns the gene CHIA and gastric cancer.